secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2023-01-06T23:59:59+00:00
Accession:  0001664710-23-000003
Event type: other_material
Sentiment:  neutral
Materiality: 0.35
Item codes: 1.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros amends lease for 35,662 sq ft in Lexington; 8-year term, base rent $202K/mo
--------------------------------------------------------------------------------

- Phase A (31,991 sq ft) delivered Jan 4, 2023; Phase B (3,671 sq ft vivarium) due by May 1, 2023.
- Base rent starts earlier of 8 months post Phase B or 11 months post Phase A delivery.
- Initial monthly base rent $202,084.66, escalating ~3% annually.
- Lease term is 8 years from Phase A commencement.
- Landlord is Revolution Labs Owner, LLC; premises at 1050 Waltham St, Lexington, MA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000003/0001664710-23-000003-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471023000003/kros-20230106.htm
  HTML page:      https://secwatch.observer/filing/0001664710-23-000003

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer